TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04643379
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Supplied by Merck \& Co.
Study: NCT04643379
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially available
Study: NCT05826509
Drug: Peri-operative darolutamide + surgery.
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide: 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg; for a total duration of 9 months. Darolutamide will start at day 1.~Surgery: radical prostatectomy with lymph node dissection will be performed after at least 3 months of darolutamide treatment.
Study: NCT04638309
Drug: APR-548 + Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
Study: NCT06424301
Drug: Targeting NUDT21 siRNA drugs
Normalized name: Sirna-027
DrugBank: Sirna-027 (DB05896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is performed for intravitreal chemotherapy.
Study: NCT05919147
Drug: Pioglitazone 45 mg
Normalized name: pioglitazone 45 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.
Study: NCT06299371
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab IV
Study: NCT06299371
Drug: paclitaxel for injection (albumin bound)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel for injection (albumin bound) IV
Study: NCT06299371
Drug: Cisplatin or Carboplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin or Carboplatin IV
Study: NCT05631678
Drug: ASK120067;itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
Study: NCT06280976
Drug: Aspirin tablet
Normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin 81 mg po qd
Study: NCT05063149
Drug: Broncho-Vaxom
Normalized name: Broncho-Vaxom
DrugBank: OM85 (DB16533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
Study: NCT06652685
Drug: D5-PBCR(-) IA arm
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: IA Drug: idarubicin, intravenously, 10 mg/m\^2 on D1-3 Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group with favorable/intermediate risk and MRD negetive, will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses. Subjects in the group with adverse risk or MRD positive will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status.
Study: NCT06652685
Drug: D5-PBCR(+) IA+Venetoclax arm
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: IA+Ven Drug: idarubicin, intravenously, 10 mg/m\^2, on D1-3, Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7 For D5-PBCR (+) patients, Venetoclax will be combined. Drug: Venetoclax. Orally once daily, on D6-14. A 3-day dose ramp-up is required for the first induction (100mg D6, 200mg D7, 400mg D8-14) If a second induction is needed, the dose of IA is the same as the first cycle, and dose ramp-up of venetoclax is not required.~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status.
Study: NCT06280976
Drug: Nexlizet
Normalized name: Nexlizet
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: bempedoic acid-ezetimibe 180-10 mg po qd
Study: NCT06280976
Drug: LEQVIO
Normalized name: Leqvio
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: inclisiran SQ as per product insert
Study: NCT06280976
Drug: Vascepa
Normalized name: Vascepa
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: icosapent ethyl 2g PO BID
Study: NCT06280976
Drug: Jardiance
Normalized name: Jardiance
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: empagliflozin 10 mg PO QD
Study: NCT06280976
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.5 MG po qd
Study: NCT04576507
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigates two strengths of cannabis.
Study: NCT04221750
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
Study: NCT06005324
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given as part of induction chemotherapy.
Study: NCT06005324
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given as part of induction chemotherapy.
Study: NCT06005324
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given as part of induction chemotherapy.
Study: NCT06701344
Drug: Golidocitinib
Normalized name: Golidocitinib
DrugBank: Golidocitinib (DB18057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Treatment:~Complete remission patients will further divide into two groups. Unfit, frail old patients will receieve Golidocitinib 150mg QD for two years. Fit, young patients will receive ASCT.
Study: NCT06700681
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TIVA induction and maintain with Propofol.
Study: NCT06700681
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TIVA induction and maintain with Remimazolam.
Study: NCT04815408
Drug: BGB-A317
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody，Tislelizumab (BGB-A317)
Study: NCT04815408
Drug: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
Study: NCT06005324
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
Study: NCT05212857
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given subcutaneously or as an injection
Study: NCT05212857
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given subcutaneously or as an injection
Study: NCT05212857
Drug: Triptorelin acetate
Normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given subcutaneously or as an injection
Study: NCT05212857
Drug: Degarelix acetate
Normalized name: Degarelix acetate
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given subcutaneously or as an injection
Study: NCT05212857
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT05212857
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT05212857
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT06702826
Drug: Cadonilimab combined with SRS
Normalized name: miconazole
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone
Study: NCT04717830
Drug: Gamezumab
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for infusion
Study: NCT00000803
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000803
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000803
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05196711
Drug: MAX-40070
Normalized name: Bronkaid Max
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days.
Study: NCT06702566
Drug: chemotherapy drugs
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy drugs are determined based on the investigator's decision.
Study: NCT06703437
Drug: Dehydrated alcohol
Normalized name: DEHYDRATED ALCOHOL
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-acting neuraxial blockade at the time of prostate biopsy by periprostatic injection of Dehydrated alcohol.
Study: NCT06703437
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: By periprostatic injection, 2mL
Study: NCT06703047
Drug: ATRA+pd-1+chemo
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
Study: NCT06703047
Drug: placebo+PD-1+chemo
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
Study: NCT04942964
Drug: Bocidelpar
Normalized name: Bocidelpar
DrugBank: Bocidelpar (DB16906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04950608
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, single administration, dosage 25 mg orally
Study: NCT05268627
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: endoscopy
Study: NCT04444362
Drug: Intestinal Microbiota Transplant (IMT) Capsules
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestinal Microbiota Transplant (IMT) Capsules tid immediately after cardiovascular surgery for at least 7 days
Study: NCT04848337
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
Study: NCT04848337
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib 20 mg orally daily.
Study: NCT06087419
Drug: chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)
Study: NCT06087419
Drug: Venetoclax Oral Tablet
Normalized name: venetoclax Oral Tablet
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)
Study: NCT06087419
Drug: Inotuzumab Ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)
Study: NCT05442216
Drug: Tagraxofusp (Cycles 1-2)
Normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12 mcg/kg intravenously Days 1-5
Study: NCT05442216
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
Study: NCT05442216
Drug: Tagraxofusp (Cycles 3-12)
Normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12 mcg/kg intravenously Days 1-3
Study: NCT05918133
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04788615
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20mg Subcutaneous injection
Study: NCT06477783
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.
Study: NCT05595447
Drug: Brentuximab Vedotin 50 MG [Adcetris]
Normalized name: brentuximab vedotin 50 MG [Adcetris]
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1
Study: NCT05880862
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually titrated Mirabegron, starting at 25 mg daily and increased to 50 mg daily at 6-weeks, during the 12-week intervention period.
Study: NCT05880862
Drug: Trospium Chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 12-week course of Trospium XL -extended release, 60mg once daily.
Study: NCT05963997
Drug: Samuraciclib
Normalized name: Samuraciclib
DrugBank: Samuraciclib (DB16061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samuraciclib capsules by mouth once a day
Study: NCT05963997
Drug: Elacestrant Dihydrochloride
Normalized name: elacestrant dihydrochloride
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elacestrant tablets by mouth once a day
Study: NCT05341583
Drug: Ensartinib
Normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
Study: NCT05565105
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).
Study: NCT05565105
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
Study: NCT05565105
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan: 70 mg/m\^2/day x 2
Study: NCT05565105
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine: 25 mg/m\^2/day x 5
Study: NCT05674864
Drug: Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus
Normalized name: Bifidobacterium animalis / Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
Study: NCT06425419
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 micrograms of intravitreal topotecan given in a 1 cc tuberculin syringe at a concentration of 20 mcg/20mcL.
Study: NCT04801940
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 2.5mg orally twice daily for 14 days.
Study: NCT04801940
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40mg orally once daily for 12 months.
Study: NCT06619015
Drug: Pramlintide Acetate 1 MG/ML
Normalized name: pramlintide acetate 1 MG/ML
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Symlin (R) (Pramlintide acetate) 1000mcg/ml, will be administered as a continuous infusion at a rate of 15mcg/hour, equivalent to the daily recommended maximum dosage of 360mcg/day.
Study: NCT06619015
Drug: Semaglutide Pen Injector
Normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide from 0,25mg/week to 2,4mg/week
Study: NCT05981118
Drug: Betamethasone dipropionate 0.05%
Normalized name: BETAMETHASONE DIPROPIONATE 0.05% OINT
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.05% cream group will be treated once daily on both legs until clear or up to 12 weeks
Study: NCT05981118
Drug: Tapinarof
Normalized name: Tapinarof
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks
Study: NCT06619015
Drug: Sodium Chloride 0.9% Inj
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT04774926
Drug: Brolucizumab
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 120 mg/ml solution for intravitreal injection
Study: NCT06255366
Drug: Caroxime sodium sulfonate
Normalized name: Sodium Polystyrene Sulfonate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
Study: NCT06255366
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
Study: NCT06255366
Drug: 0.9% Sodium Chloride Injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
Study: NCT05696847
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06186076
Drug: TRX-221
Normalized name: TRX-0237
DrugBank: Hydromethylthionine mesylate (DB16899)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRX-221 oral dose as defined
Study: NCT06027437
Drug: Danicamtiv
Normalized name: Danicamtiv
DrugBank: Danicamtiv (DB18962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days.
Study: NCT04698850
Drug: Aflibercept 40 MG/ML [Eylea]
Normalized name: aflibercept 40 MG/ML [Eylea]
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..
Study: NCT04698850
Drug: Brolucizumab-Dbll 120 MG/ML [Beovu]
Normalized name: brolucizumab-dbll 120 MG/ML [Beovu]
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.
Study: NCT04698850
Drug: Ranibizumab 6 MG/ML [Lucentis]
Normalized name: ranibizumab 6 MG/ML [Lucentis]
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
Study: NCT04789148
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 IU intranasal oxytocin, 24 IU intranasal oxytocin or placebo